Andreas Kronbichler
1*, Gert Mayer
11 Medical University Innsbruck, Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck, Austria
*Corresponding Author: Corresponding author: Dr. Andreas Kronbichler, Medical University Innsbruck, Department of Internal Medicine IV, Nephrology, Email:
andreas.kronbichler@i-med.ac.at
Implication for health policy/practice/research/medical education:
Reports on patients with steroid-dependent nephrotic syndrome and
underlying minimal change disease or focal segmental glomerulosclerosis
have shown promising results. There is a strong need for more trials
conducted in a prospective, controlled manner to clearly recommend
rituximab therapy in this indication on a regular basis.
Please cite this paper as: Kronbichler A, Mayer G. Nephrotic Syndrome: is rituximab
the light at the end of the tunnel in the treatment of adult steroid-dependent
minimal change disease and focal segmental glomerulosclerosis? J Nephropathol.
2014; 3(1): 1-3. DOI: 10.12860/jnp.2014.01